• FirefoxTry Yahoo Finance on Firefox »
  •  Dow Up1.09% Nasdaq Up0.98%

    More On B8F.DE



    News & Info


    Analyst Coverage

    • Analyst Opinion
    • Analyst Estimates


    • Major Holders
    • Insider Transactions
    • Insider Roster


    Biofrontera AG (B8F.DE)

    2.13 Up 0.05(2.35%) Jul 28
    Add to Portfolio
    ProfileGet Profile for:
    Biofrontera AG
    Hemmelrather Weg 201
    Leverkusen, 51377
    Germany - Map
    Phone: 49 214 87 63 210
    Fax: 49 214 87 63 290
    Website: http://www.biofrontera.com

    Index Membership:N/A
    Full Time Employees:49

    Business Summary 

    Biofrontera AG, a biopharmaceutical company, primarily focuses on the discovery, development, and distribution of dermatological drugs and dermatological-tested cosmetics for the treatment and care of diseased skin. The company’s products include Ameluz, a prescription drug for the treatment of actinic keratosis, a superficial skin cancer; BF-RhodoLED, a lamp for photodynamic therapy with LEDs emitting red light at an average wavelength of 635 nm; Belixos, a cream with herbal ingredients for the care of inflamed, itchy, and flaky skin, such as localized itching, insect bites, burns, nuerodermatitis, and psoriasis; Belixos LIQUID to treat itching and scaliness, and restore the scalp’s natural balance; and Belixos GEL for use on inflamed and reddened skin, and skin prone to impurities. It is also developing BF-derm1, which is in Phase II clinical trial for the treatment of chronic and antihistamine-refractory urticaria; and BF-1, a serotonin receptor antagonist that is in Phase I clinical trial to treat migraine prophylaxis. The company was founded in 1997 and is headquartered in Leverkusen, Germany.

    Key Statistics

    Company Websites 
    Home Page
    Search Yahoo! for:
    More on Biofrontera AG

    Key Executives 
    Prof. Hermann L Ph.D., 59
    Co-Founder, Chairman of Management Board and Chief Exec. Officer
    Mr. Thomas Schaffer ,
    Chief Financial Officer and Member of Management Board
    Mr. Fabian Esser Ph.D.,
    Head of Marketing & Sales
    Ms. Monica Tamborini , 59
    Chief Exec. Officer of Biofrontera at US Operations
    Amounts are as of Dec 31, 2014 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc.Exercised is the value of options exercised during the fiscal year.
    Currency in EUR.